Therapy Areas: Vaccines
Meissa Vaccines Touts Positive Interim Clinical Data for Its Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine Candidate for Infants
8 November 2022 - - US-based clinical-stage biotechnology company Meissa Vaccines has posted interim clinical data of MV-012-968, Meissa's intranasal live attenuated RSV vaccine candidate, from a Phase 1c study in RSV-naïve (seronegative) infants and young children, the company said.

Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and young children from RSV. The data were presented at the 7th International Conference on Vaccines Research and Development.

The study enrolled 66 participants between the ages of six and 36 months at multiple sites in the US to evaluate the safety and immunogenicity of MV-012-968 ( Identifier: NCT04909021).

Meissa's intranasal live attenuated RSV vaccine was well-tolerated with no safety concerns identified, no serious adverse events to-date, and negligible vaccine virus shedding. Solicited symptoms were generally mild and did not differ in incidence from the placebo group.

At the highest dose regimen studied to date (two doses of 106 PFU), the vaccine stimulated a serum neutralizing antibody response in 78% of RSV-naïve children. Taken together with nasal IgA responses, the vaccine induced an immune response in 89% of RSV-naïve children.

RSV is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants. In the United States, approximately 1% of infants are hospitalized because of RSV each year.

Globally, in children under five years of age, RSV causes more than 66,000 deaths per year and approximately three m hospitalizations (Anderson 2013).

Since the discovery of RSV in 1956, no vaccine has been approved for prevention.

Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from respiratory syncytial virus.

MV-012-968 was generated using the company's proprietary AttenuBlock synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.

Meissa's live attenuated intranasal vaccines for RSV and SARS-CoV-2 (COVID-19) are built on the company's proprietary AttenuBlock platform to achieve appropriate attenuation, genetic stability, and optimized immunity.

Injectable vaccines typically induce only serum antibodies that circulate in the blood and are important for preventing serious lung disease.

Intranasal vaccines generate serum IgG and mucosal antibodies in the nasal cavity, which are essential for blocking infection and transmission of respiratory viruses, like RSV and SARS-CoV-2.

Meissa's vaccine platform and intranasal vaccine strategy are uniquely designed to confer mucosal immunity that will likely reduce transmission, if compared to injectable vaccines, provide long-lasting protection, and be a part of the global solution to controlling respiratory viruses.

Meissa Vaccines was founded with a mission to protect people everywhere from life-threatening respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale.

Meissa is advancing intranasal, live attenuated vaccine candidates against respiratory syncytial virus, SARS-CoV-2 (COVID-19), and human metapneumovirus.

These vaccine candidates have been developed using the company's proprietary AttenuBlock platform, which includes codon deoptimization and technologies exclusively licensed from Emory University and Children's Healthcare of Atlanta.

Meissa's live attenuated vaccine candidates are formulated to be delivered as an adjuvant-free, needle-free dose and are designed to generate a strong, durable immune response to prevent infection and disease.

Meissa is headquartered in Redwood City, California.